These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29110244)

  • 1. The Effect of 6 and 12 months Duodenal-Jejunal Bypass Liner Treatment on Obesity and Type 2 Diabetes: a Crossover Cohort Study.
    van Rijn S; Betzel B; de Jonge C; van Dijk DPJ; Janssen IM; Berends FJ; Bouvy ND; Greve JWM
    Obes Surg; 2018 May; 28(5):1255-1262. PubMed ID: 29110244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial.
    Koehestanie P; de Jonge C; Berends FJ; Janssen IM; Bouvy ND; Greve JW
    Ann Surg; 2014 Dec; 260(6):984-92. PubMed ID: 25072436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study.
    Laubner K; Riedel N; Fink K; Holl RW; Welp R; Kempe HP; Lautenbach A; Schlensak M; Stengel R; Eberl T; Dederichs F; Schwacha H; Seufert J; Aberle J
    Diabetes Obes Metab; 2018 Aug; 20(8):1868-1877. PubMed ID: 29569313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study.
    Betzel B; Homan J; Aarts EO; Janssen IMC; de Boer H; Wahab PJ; Groenen MJM; Berends FJ
    Surg Endosc; 2017 Jul; 31(7):2881-2891. PubMed ID: 27804045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in BMI, Glycemic Control and Obesity-Associated Comorbidities After Explantation of the Duodenal-Jejunal Bypass Liner (DJBL).
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Obes Surg; 2018 Aug; 28(8):2187-2196. PubMed ID: 29504053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner.
    Riedel N; Laubner K; Lautenbach A; Schön G; Schlensak M; Stengel R; Eberl T; Dederichs F; Aberle J; Seufert J
    Surg Obes Relat Dis; 2018 Jun; 14(6):769-779. PubMed ID: 29650340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is reimplantation of the duodenal-jejunal bypass liner feasible?
    Koehestanie P; Betzel B; Aarts EO; Janssen IM; Wahab P; Berends FJ
    Surg Obes Relat Dis; 2015; 11(5):1099-104. PubMed ID: 25979208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.
    Gersin KS; Rothstein RI; Rosenthal RJ; Stefanidis D; Deal SE; Kuwada TS; Laycock W; Adrales G; Vassiliou M; Szomstein S; Heller S; Joyce AM; Heiss F; Nepomnayshy D
    Gastrointest Endosc; 2010 May; 71(6):976-82. PubMed ID: 20304396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner.
    Escalona A; Pimentel F; Sharp A; Becerra P; Slako M; Turiel D; Muñoz R; Bambs C; Guzmán S; Ibáñez L; Gersin K
    Ann Surg; 2012 Jun; 255(6):1080-5. PubMed ID: 22534421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is duodeno-jejunal bypass liner superior to pylorus preserving bariatric surgery in terms of complications and efficacy?
    Balint IB; Csaszar F; Somodi K; Ternyik L; Biro A; Kaposztas Z
    Langenbecks Arch Surg; 2021 Aug; 406(5):1363-1377. PubMed ID: 33712874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial.
    van Rijn S; Roebroek YGM; de Jonge C; Greve JWM; Bouvy ND
    Obes Surg; 2019 Apr; 29(4):1117-1121. PubMed ID: 30627989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation.
    Betzel B; Cooiman MI; Aarts EO; Janssen IMC; Wahab PJ; Groenen MJM; Drenth JPH; Berends FJ
    Surg Endosc; 2020 Jan; 34(1):209-215. PubMed ID: 30877567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the Duodeno-Jejunal Bypass Liner in Patients With Metabolic Syndrome: A Multicenter Randomized Controlled Trial (ENDOMETAB).
    Caiazzo R; Branche J; Raverdy V; Czernichow S; Carette C; Robert M; Disse E; Barthet M; Cariou B; Msika S; Behal H; Denies F; Dervaux B; Duhamel A; Verkindt H; Pattou F
    Ann Surg; 2020 Nov; 272(5):696-702. PubMed ID: 32889869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus.
    Kaválková P; Mráz M; Trachta P; Kloučková J; Cinkajzlová A; Lacinová Z; Haluzíková D; Beneš M; Vlasáková Z; Burda V; Novák D; Petr T; Vítek L; Pelikánová T; Haluzík M
    J Endocrinol; 2016 Oct; 231(1):11-22. PubMed ID: 27474690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
    Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
    Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effectiveness and Safety of the Duodenal-Jejunal Bypass Liner (DJBL) for the Management of Obesity and Glycaemic Control: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yvamoto EY; de Moura DTH; Proença IM; do Monte Junior ES; Ribeiro IB; Ribas PHBV; Hemerly MC; de Oliveira VL; Sánchez-Luna SA; Bernardo WM; de Moura EGH
    Obes Surg; 2023 Feb; 33(2):585-599. PubMed ID: 36508156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety experience with the duodenal-jejunal bypass liner: an endoscopic treatment for diabetes and obesity.
    Betzel B; Koehestanie P; Aarts EO; Dogan K; Homan J; Janssen IM; Wahab PJ; Groenen MJ; Berends FJ
    Gastrointest Endosc; 2015 Nov; 82(5):845-52. PubMed ID: 25952090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids.
    Glaysher MA; Ward J; Aldhwayan M; Ruban A; Prechtl CG; Fisk HL; Chhina N; Al-Najim W; Smith C; Klimowska-Nassar N; Johnson N; Falaschetti E; Goldstone AP; Miras AD; Byrne JP; Calder PC; Teare JP
    Clin Nutr; 2021 Apr; 40(4):2343-2354. PubMed ID: 33131909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
    Jirapinyo P; Haas AV; Thompson CC
    Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of duodenal-jejunal bypass liner for obesity and type 2 diabetes: A systematic review and meta-analysis.
    Chen W; Feng J; Dong S; Guo J; Zhou F; Hu S; Hu R; Wang C; Ma Y; Dong Z
    Obes Rev; 2024 Nov; 25(11):e13812. PubMed ID: 39191438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.